FindTrial
Sign In

Recombinant luteinizing hormone (rLH) for expected poor prognosis patients in IVF/ICSI cycles

Additional rLH improves live birth rates in expected poor prognosis patients in IVF/ICSI cycles

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043040
Enrollment
Unknown
Registered
2021-02-04
Start date
2021-04-01
Completion date
Unknown
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Expected poor prognosis patients

Interventions

rLH group:Adding rLH (Luveris) 75IU/d on day 2-3 until HCG administration
control group:no rLH

Sponsors

West China Second University Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
No minimum to 44 Years

Inclusion criteria

Inclusion criteria: 1. Aged <= 44 years; 2. AFC < 5 or AMH < 1.2 ng/ml.

Exclusion criteria

Exclusion criteria: 1. Natural cycles, micro-stimulation cycles or PPOS protocol; 2. Pre-implantation genetic test cyles or donated oocyte cycles; 3. Hypogonadotropic hypogonadism; 4. Allergic to LH products; 5. Tumor history or suspected tumor; 6. Unexplained ovarian enlargement.

Design outcomes

Primary

MeasureTime frame
live birth rate;—

Countries

China

Contacts

Public ContactXiaohong Li

West China Second University Hospital, Sichuan University

lixiaohongham_001@163.com+86 13880087083

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026